Bronchogen is a synthetic bioregulatory tetrapeptide investigated in cellular and tissue models to analyze pulmonary gene expression, epithelial differentiation, and mucosal barrier dynamics. Supplied exclusively as a high-purity research compound for in vitro and preclinical laboratory evaluation, it serves as a valuable tool for structural and genomic research.
Bronchogen is a synthetic bioregulatory tetrapeptide investigated in cellular and tissue models to analyze pulmonary gene expression, epithelial differentiation, and mucosal barrier dynamics. Supplied exclusively as a high-purity research compound for in vitro and preclinical laboratory evaluation, it serves as a valuable tool for structural and genomic research.
Bronchogen is a synthetic bioregulatory tetrapeptide composed of the amino acid sequence L-alanyl-L-alpha-aspartyl-L-alpha-glutamyl-L-leucine (Ala-Asp-Glu-Leu). Developed within the framework of short peptide chromatin interactions, it is primarily studied in preclinical laboratory models to evaluate its effects on bronchial epithelial cell differentiation, gene expression, and pulmonary tissue homeostasis strictly for research applications.
As part of the short-chain peptide bioregulator family, Bronchogen is designed to mimic signaling sequence fragments naturally found in tissue-specific peptide pools. Investigated across various cell culture and tissue-slice models, scientists utilize the peptide to map epigenetic regulation, cytoprotective responses to environmental oxidants, and structural protein synthesis in respiratory line assays. Researchers seeking to study these pathways can source verified sequences through our all peptides catalog for standardized testing.
The molecular architecture of Bronchogen consists of four amino acids arranged in the sequence Ala-Asp-Glu-Leu (monoisotopic mass approximately 460.48 g/mol). Featuring two acidic residues (Aspartic acid and Glutamic acid) coupled with hydrophobic terminals (Alanine and Leucine), the peptide exhibits distinct charge characteristics at physiological pH values. This specific structural charge profile enables high solubility in aqueous buffer systems commonly used in cell culture and biochemical protocols.
In structural biochemistry, short tetrapeptides like Bronchogen are examined for their ability to traverse nuclear membranes without requiring active transport chaperones. Preclinical literature suggests that the physical dimensions and spatial charge distribution of Ala-Asp-Glu-Leu allow direct stereospecific interaction with the major and minor grooves of double-stranded DNA. This property makes the sequence an optimal model compound for studying non-enzymatic chromatin unfolding and histone modification in vitro.
Preclinical investigations into Bronchogen focus largely on its capacity to modulate transcription factor activity and chromatin accessibility within respiratory tissue models. In vitro studies utilizing primary human bronchial epithelial cells (HBECs) demonstrate that exposure to short bioregulatory peptides alters the transcription rates of genes associated with ciliary function, mucin production, and intercellular junction integrity (such as claudins and occludins).
At the subcellular level, researchers hypothesize that Bronchogen binds selectively to specific promoter regions of genes encoding anti-inflammatory proteins and antioxidant enzymes, including superoxide dismutase (SOD) and glutathione peroxidase. By facilitating a localized uncoiling of condensed heterochromatin, the peptide appears to promote RNA polymerase access without inducing structural genomic alterations. These non-mutagenic transcriptional adjustments provide a controlled model for analyzing cellular recovery following toxicological or oxidative challenges in laboratory assays.
Animal model studies and organotypic tissue slice culture assays have provided substantial observational data regarding the impact of Bronchogen on airway tissues. In rodent models subjected to simulated chronic environmental exposure or inflammatory challenge, administration of the peptide was observed to modulate neutrophil infiltration and attenuate hyper-reactive remodeling of the bronchoalveolar extracellular matrix. These findings, detailed in comparative research library articles, underline its utility in pulmonary pathology research.
Furthermore, in vitro organ culture experiments involving tracheal explants indicate that Bronchogen supports the preservation of ciliated cell density and maintains baseline surfactant protein expression under stress conditions. The peptide does not demonstrate direct antimicrobial activity, but preclinical findings suggest it supports native cellular defense mechanisms by upregulating endogenous expression of antimicrobial peptides like beta-defensins in epithelial layers.
When evaluating short-chain synthetic bioregulators, comparing specific sequence targets assists researchers in selecting the appropriate peptide model for their experimental design. While Bronchogen (Ala-Asp-Glu-Leu) is optimized for pulmonary and bronchial cell line investigations, other sequence formulations target distinct organ systems or systemic physiological pathways.
For instance, Cartalax (Ala-Asp-Glu) is utilized primarily in cartilage and connective tissue repair models, targeting chondrocyte extracellular matrix expression. Similarly, Vilon (Lys-Glu) focuses on immune cell modulation and thymic stromal signaling, whereas Epitalon (Ala-Glu-Asp-Gly) is widely studied for its interaction with telomerase dynamics and pineal gland activity. Researchers evaluating broad cytoprotective mechanisms may also compare Bronchogen against non-bioregulator repair compounds such as BPC-157 or immune-modulating chains like Thymalin to establish comparative tissue-specificity benchmarks.
To maintain analytical integrity during in vitro assays, appropriate preparation and handling of high-purity Bronchogen is critical. The lyophilized peptide powder should be solubilized under sterile conditions using sterile target-grade solvents such as Bacteriostatic Water, Phosphate-Buffered Saline (PBS, pH 7.4), or standard cell culture media. Due to its balanced hydrophilic and hydrophobic amino acid composition, Bronchogen rapidly dissolves without requiring aggressive vortexing or co-solvents like DMSO.
When preparing stock solutions for cell culture protocols, stock concentrations ranging from 1 mg/mL to 10 mg/mL are standard. Once reconstituted in liquid buffer, solutions should be aliquot-divided into single-use polypropylene microtubes to prevent degradation caused by repeated freeze-thaw cycles. Detailed volumetric preparation workflows can be evaluated using standard laboratory reference protocols across our research peptides product line.
Lyophilized Bronchogen powder exhibits strong thermal stability when stored under controlled conditions. For long-term preservation exceeding three months, the solid peptide should be kept at -20°C or -80°C in a desiccated container protected from light. Under these conditions, the peptide maintains structural integrity and sequence fidelity without significant hydrolytic degradation.
Upon reconstitution, liquid stock solutions should be stored at 2°C to 8°C and utilized within 7 to 14 days to prevent microbial contamination or slow peptide bond cleavage. For extended assay series requiring reconstituted material over several months, aliquots must be flash-frozen and kept below -20°C. Ambient temperature exposure during transit or bench top preparation should be minimized, although short-term room-temperature exposure during shipping does not compromise lyophilized peptide purity.
Experimental reproducibility relies entirely on chemical purity and exact sequence confirmation. PX1 Research subjects every lot of Bronchogen to rigorous analytical testing in an ISO 17025 accredited laboratory facility. Structural verification and sequence purity are measured using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) paired with Electrospray Ionization Mass Spectrometry (ESI-MS).
Each batch must demonstrate a minimum peptide purity of 98.0%, accompanied by a lot-specific Certificate of Analysis (COA) displaying precise chromatographic peak retention and molecular mass correlation. Furthermore, because cell line cultures—particularly primary pulmonary lines—are exceptionally sensitive to bacterial contaminants, every lot undergoes chromogenic LAL testing to verify endotoxin levels remain strictly below <0.05 EU/mg. Institutional buyers managing high-volume screening programs can review specialized testing parameters via our wholesale portal.
Procuring reliable research compounds requires supplier transparency and strict adherence to manufacturing protocols. PX1 Research synthesizes Bronchogen exclusively within USA-based, GMP-compliant facilities. This ensures rigorous control over amino acid coupling efficiency, TFA salt removal, and final lyophilization conditions.
By enforcing batch-level lot traceability from synthesis through final packaging, PX1 Research eliminates variability across experimental replicates. Orders ship directly from our California and Arizona fulfillment centers with same-day processing for orders placed Monday through Friday, ensuring rapid, temperature-stable delivery for laboratory projects across North America.
What is Bronchogen and what is its amino acid sequence?
Bronchogen is a synthetic short bioregulatory tetrapeptide with the amino acid sequence L-alanyl-L-alpha-aspartyl-L-alpha-glutamyl-L-leucine (Ala-Asp-Glu-Leu or KEDL equivalent in sequence classification). It is designed for laboratory research investigating bronchial and pulmonary cell dynamics.
Is Bronchogen intended for human medical use or clinical administration?
No. Bronchogen is strictly a research compound manufactured and sold exclusively for in vitro laboratory testing, academic research, and preclinical analytical assays. It is not for human or veterinary consumption, therapy, or clinical application.
How is the purity of Bronchogen verified?
Every lot of Bronchogen from PX1 Research is analyzed via RP-HPLC to confirm a purity standard of ≥98.0%. Sequence identity and molecular mass are confirmed using ESI Mass Spectrometry, and batch data is published on a lot-specific Certificate of Analysis.
What solvents are recommended for reconstituting Bronchogen in vitro?
Bronchogen easily dissolves in sterile Phosphate-Buffered Saline (PBS, pH 7.4), sterile laboratory-grade water, or standard cell culture media (e.g., DMEM or RPMI-1640) without needing harsh organic co-solvents.
What are the endotoxin limits for PX1 Research Bronchogen?
Bronchogen batches undergo chromogenic Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain strictly under <0.05 EU/mg, preventing endotoxin-induced background artifact in delicate epithelial cell assays.
How does Bronchogen compare to other short peptides like Epitalon or Cartalax?
While all belong to the short-chain bioregulator family, Bronchogen (Ala-Asp-Glu-Leu) specifically targets respiratory epithelial cell pathways. In contrast, Cartalax targets chondrocytes/connective tissue, and Epitalon regulates telomerase and neuroendocrine markers.
What are the ideal storage conditions for lyophilized Bronchogen?
Lyophilized Bronchogen should be stored at -20°C or -80°C in a dry, dark environment. Stored under these conditions, the powder remains stable for up to 24 months.
Can institutions purchase bulk quantities of Bronchogen for high-throughput screening?
Yes. Institutional laboratories and academic facilities can request bulk production runs and custom batch sizing through the PX1 Research wholesale program, supported by complete analytical documentation.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.